Exclusion criteria
Children with one of more of the following were not eligible for inclusion:
 Current involvement in another clinical trial of an investigational medicinal product (CTIMP) or have participated in a CTIMP during the last 4 months,  Current systemic infection or ear infection,  Cleft palate, Down's syndrome, diabetes mellitus, Kartagener's or Primary Ciliary Dyskinesia, renal failure, hypertension or congestive heart failure,  Confirmed, major developmental difficulties (e.g. are tube fed, have chromosomal abnormalities),  Existing known sensory hearing loss,  Taken oral steroids in the preceding 4 weeks,  Had a live vaccine in the preceding 4 weeks if aged under 3 years,  Has a condition that increases their risk of adverse effects from oral steroids (i.e. on treatment likely to modify the immune system or who are immunocompromised, such as undergoing cancer treatment),  Has been in close contact with someone known or suspected to have Varicella (chicken pox) or active Zoster (Shingles) during the 3 weeks prior to recruitment and have no prior history of Varicella infection or immunisation,  Already has ventilation tubes (grommets),  On a waiting list for grommet surgery and anticipate having surgery within 5 weeks and are unwilling to delay it.
Changes to methods
The main changes to the protocol that occurred during the conduct of the trial are summarised below:
A number of changes were made to the protocol to make it easier for sites to recruit patients and schedule the follow-up appointments. For example, we extended our site coverage into England, the eligibility criteria for audiometry confirmed hearing loss was extended to 14 days preceding recruitment, follow-up visits were conducted in ENT or Audiology outpatient clinics, the timeframe windows for follow-up were extended to + 2 weeks for 5-week follow-up, and +/-2 weeks for 6 and 12 month follow-ups. Paediatric Audiology and AVM Clinics were included as sites, and Audiovestibular Physicians were included as designated OSTRICH clinicians.
Additions were made to the exclusion criteria such as ear infections, Kartagener's or Primary Ciliary Dyskinesia, existing known sensory hearing loss, undergoing cancer treatment, on a waiting list for grommet surgery and anticipated having surgery within 5 weeks and unwilling to delay it, live vaccines 4 weeks prior to recruitment if aged under 3 years old.
A number of changes to the planned trial procedures were made due to time constraints resulting from the longer than anticipated recruitment period. For example, removal of medical notes search and data linkage used to identify healthcare consultations during the 12 month follow-up period in secondary care and primary care. As a result of this, a specific assessment of resource use at baseline could not be collected.
Lastly, a number of further amendments were made to the protocol such as sending reminders for follow-up appointments and contacting parents regarding missed appointments and exploratory analysis to assess association between baseline hearing threshold and quality of life. We also undertook a qualitative sub-study to explore parents' understanding of the treatment options available to them, their views on shared decision making in the context of managing glue ear and their views on the use of oral steroids for glue ear.
The following changes were added to the statistical analysis plan following publication of the protocol paper and approved by the IDMC:
1. For the primary outcome, in addition to adjusting for child's age at recruitment, site and time to followup were also deemed important to adjust for. 2. A negative binomial model was used instead of the intended Poisson model due to over dispersion. 3. For the symptoms scores, a component was added to combine each individual symptom score into an overall score so that the issue of multiple outcomes were overcome.
The following changes were omitted from the SAP following publication of the protocol paper: 1. Given the limited number of weeks of follow-up, duration between start and resolution of symptom was not examined and modelled using a time to event (Cox regression) model. Instead the analysis proposed in point 3 above was included.
Further changes were made to the proposed longer-term modelling to be conducted as part of health economic analysis as a result of the trial results and these can be found in Appendix 2 of the funder's report (found at https://www.journalslibrary.nihr.ac.uk/).
3. Pre-specified sub-group analyses The sub-group analyses that were pre-specified, and undertaken, were: Category Groups Age 2-5, 6-8. 
Methods: Secondary outcomes analyses
Secondary outcomes with a binary outcome measured over several time points (audiology, tympanometry, and otoscopy) were analysed using repeated measures logistic regression and effects reported as adjusted odds ratios. For continuous outcomes (HUI3, PedsQL, and OM8-30 scores), repeated measures linear regression models were run, adjusting for baseline scores and the effect of oral steroids reported as adjusted differences in mean scores. Transformations (squared and cubed) to the raw scores were performed as necessary to improved residuals and model fit. If no transformations were suitable, the raw scores were dichotomised and a repeated measures logistic regression model used. All repeated measures models investigate differences in trial groups and over time, and included an interaction term for time and group to investigate any divergent or convergent pattern in outcomes. Weekly scores were reported on the child's symptoms on a scale of 0 to 6 (not present to as bad as it could be) for eight symptoms (any problems with hearing, ear pain, speech, energy levels, sleep, attention span, balance, being generally unwell). Cronbach's alpha and factor analysis confirmed that the symptoms could be combined in an overall score. Effect of oral steroids on weekly overall scores was examined using a repeated measures linear model. Changes in nausea and behaviour in mood over time were similarly examined. An adjusted multilevel Cox (shared frailty) regression model examined the days since recruitment to insertion of ventilation tubes and treatment effect reported as an adjusted hazard ratio (aHR). Days off school/work/OME related healthcare consultations were analysed using a Negative Binomial model and effects presented as an adjusted incident rate ratio (aIRR) (oral steroid compared to placebo).
Methods: Health economic analyses
Discounting was not applied because the trial duration was only 12 months. Costs of the course of oral steroids was calculated and combined with differences in costs between intervention and control groups to determine overall costs associated with the intervention. The resource utilisation of both groups (consultations, medications, operations, equipment, etc.) and treatments associated with adverse events, were assessed through the completion of self-completed questionnaires included in the parent diary at baseline, five weeks, six months and 12 months and translated into costs using appropriate published unit costs. 1 All costs were recorded on 2015-16 prices in pound (£) sterling. The cost of a 7-day course or oral soluble Prednisolone, weighted for the different prescription dosage based on age was estimated to be £59 (taking into account the prescription dispensing cost, this figure rises to £62).
The cost effectiveness analysis compared the incremental changes in costs with the differences in primary outcome and PedsQL sore; with a cost utility analysis Quality Adjusted Life Years (QALYs) computed from HUI3 score and from utilities derived from mapping responses to the OM8-30 questionniare.
2 Non-imputed data were used for the primary outcome to reflect the clinical analysis. A multiple imputation approach using the predictive mean matching technique was used to address issues of the assumption of data missing at random for HRQOL outcomes. 3 The multiple imputation approach included covariates to control for age, gender and site. A series of one-way sensitivity analyses were conducted to assess the impact of parameter variation on baseline estimates of the cost-effectiveness ratios with non-parametric bootstrap methods used to present costeffectiveness acceptability curves of the probability of oral steroids being considered cost-effective at different willingness to pay thresholds for the cost-utility analysis. Note: Participants could be excluded due to multiple options.
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Subgroup analyses
The following tables show each of the pre-specified subgroup analyses. All analyses adjusted for site, child's age group at recruitment (2-5, 6-8 years), and time since recruitment of 5 week assessment (days) 
Secondary outcomes -Healthcare consultations
From the 349 diaries that were returned by parents (oral steroid 179; placebo 170), the total number of healthcare consultations relating to OME over the 5-week period were examined. Very few children consulted with any healthcare setting over the five weeks post randomisation (Table S4 .1) with no difference between treatment groups. Similar conclusions were found for time taken off school/nursery or days off work for family members, for ear problems and other illnesses. 15 (9) 8 (4) 0.49 (0.14 to 1.66) 0.25 a Adjusted for site, and child's age group at recruitment (2-5, 6-8 years) b Incidence rate ratio (IRR) of the oral steroid compared to placebo. An IRR< 1 indicating more events in placebo and an IRR>1 indicating more events in the oral steroid group. c Negative binomial model used due to overdispersion and is a better fitting model than Poisson (determined by Akaike Information Criterion (AIC)).
Secondary outcomes -Symptom scores
The following eight problems were combined into a single symptom scale to avoid multiple outcomes: hearing, ear pain, speech, energy levels, sleep, attention span, balance, and being generally unwell. At 1 week post randomisation, Cronbach's alpha for the eight symptom scores was 0.77 at week 1, indicating good reliability between the eight symptoms, suggesting that they could be combined into a single symptom score ranging from 0 (problems not present at all) to 48 (all problems are as bad as possible). The factor analysis also suggested that these symptoms could form a single scale. The Cronbach alpha for the subsequent four weeks were all >0.80, suggesting relatively high internal consistency over time. The distributions of the weekly overall symptom score was positively skewed indicating no problems.(The highest median scores were at the end of week 1 (7 in placebo and 6 in oral steroid) indicating that these symptoms were not a problem. When scores were changed into binary outcome (no vs. some symptoms), there was no difference between treatment groups not over time (Table S5 .1). Two categories of symptoms (nausea, vomiting or indigestion and changes in behaviour and mood over time) were examined separately; a high proportion of children had resolution of symptoms over time with no difference between treatment groups and over time. 
Health economic results
The resource utilisation questionnaires offered the relative costs associated with each group, with unit prices offered in Table S10 .1. The primary cost utility analysis (incremental cost per QALY gain at 12 months) found evidence for oral steroids being dominated (i.e. less effective and more costly) by placebo. The multiple imputed data found an insignificant incremental Quality adjusted life year decrease for the steroid group over 12 months (Table S6. 2). The cost increase of £145 and -0·015 incremental QALYs results in the steroid group being dominated by the placebo. Bootstrapping the patient level results ( Figure S6 .1) identifies that the probability of oral steroid treatment being cost-effective when compared to placebo at a £20,000 per QALY threshold is 17%, increasing slightly to 22% at a £30,000 per QALY threshold. The incremental increase in costs differs from that of the CEA due to the data treatment. Utilising the OM8-30 results to supplement the HUI3 CUA via the use of a utilities mapping technique found insignificant differences in the incremental effect, with an impact of 0·004 QALYs. £10,000 £20,000 £30,000 £40,000 £50,000 Probability
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